Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Tranzyme And BMS Sign Discovery Deal
by Ann M. Thayer
December 14, 2009
| A version of this story appeared in
Volume 87, Issue 50
Tranzyme Pharma will work to discover macrocyclic compounds directed against targets that are of interest to Bristol-Myers Squibb. BMS will pay $10 million up front and between $3 million and $6 million in R&D funding for two years. BMS will be primarily responsible for optimizing any lead compounds, as well as for further development. Tranzyme could receive milestone payments of up to $80 million for each target program. Tranzyme uses macrocyclic template chemistry to find novel bioactive macrocycles that have the potency and selectivity of biomolecules but the low production costs and high oral availability of small-molecule drugs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X